COMP <GO>
GRI vs SXTP // EV/EBITDA & P/E VALUATION
GRI Bio Inc. (NASDAQ) VS. 60 Degrees Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: GRI 1
— SXTP 2
■ METRIC PARITY
LAST: $1.57 (-3.38%) • MKT CAP: $3.4M
valuation
—
LAST: $0.95 (+11.87%) • MKT CAP: $3.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRI VS. SXTP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GRI | SXTP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 22.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 65.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 5/9 | -3.00 | SXTP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.5 | 48.6 | -5.18 | SXTP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.4M | $3.3M | $99.9K | GRI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GRI REV | SXTP REV | GRI GROSS % | SXTP GROSS % | GRI FCF | SXTP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.0M | — | 22.3% | -$10.2M | -$7.0M |
| FY 2024 | $0 | $607.6K | — | 36.7% | -$8.6M | -$5.8M |
| FY 2023 | $0 | $253.6K | — | — | -$9.0M | -$4.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRI // BETA —
SXTP // BETA —